Company / EPS (Basic)
Astria Therapeutics, Inc. EPS (Basic) History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Basic)
-$1.68
FY2024
5-year range
-$24.58 / -$1.68
FY2020-FY2024
Trend
+30.6%
vs FY2023
Sector context
#118 of 208
Health Care
What the data says
At $-1.68, Astria Therapeutics, Inc.'s eps (basic) ranks #118 of 208 in the Health Care sector. EPS (Basic) has increased for 3 consecutive years, from $-24.58 in FY2021 to $-1.68 in FY2024.
Based on SEC 10-K filings.
-1.68 in FY2024.
Improved from $-3.55 to $-1.68 over the past 2 years.
Health Care sector context is included.
EPS (Basic) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#118 of 208 in Health CareTop 57% of 208This company -$1.68 Sector average -$0.87
▼
-93.0% below sector average
Key checks
Key Insights
- Astria Therapeutics, Inc.'s eps (basic) has grown for 3 consecutive years.
- In FY2024, eps (basic) increased 30.6% year-over-year.
- Ranks #118 out of 208 companies in the Health Care sector.
- Lowest eps (basic) in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 5.45 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Basic)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$1.68 | +30.6% |
| FY2023 | -$2.42 | +31.8% |
| FY2022 | -$3.55 | +85.6% |
| FY2021 | -$24.58 | -101.5% |
| FY2020 | -$12.20 | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
| FY2015 | - | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026